Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy
Status:
Completed
Trial end date:
2017-04-19
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is
not yet known whether letrozole is more effective than a placebo in treating in women with
breast cancer who have already received 5 years of aromatase inhibitor therapy.
PURPOSE: This randomized phase III trial is studying letrozole to see how well it works
compared with a placebo in treating women with primary breast cancer who have received 5
years of aromatase inhibitor therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborators:
Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group North Central Cancer Treatment Group Southwest Oncology Group